You are here: RCJournal.com » Clinical Practice Guidelines

Reprinted from the June 2002 issue of RESPIRATORY CARE [Respir Care 2002;47(6):707–716]

AARC Clinical Practice Guideline

Selection of an Oxygen Delivery Device for Neonatal and Pediatric Patients -- 2002 Revision & Update

NPODD 1.0 PROCEDURE:
The selection of an oxygen delivery system for neonatal and pediatric patients includes patients with and without artificial airways.

NPODD 2.0 DESCRIPTION:
The administration of supplemental oxygen to neonatal and pediatric patients requires the selection of an oxygen delivery system that suits the patient's size, needs, and the therapeutic goals. Oxygen delivery systems are categorized as either low-flow (variable performance) or high-flow (fixed performance) systems.(1) Low-flow provide an FDO2 (fractional concentration of delivered oxygen) that varies with the patient's inspiratory flow and are classified as variable-performance oxygen delivery systems.(1) High-flow systems can provide a specific FDO2 at flows that meet or exceed the patient's inspiratory flow requirement and are classified as fixed-performance oxygen delivery systems.

2.1 Low-flow systems:
2.1.1 Nasal cannulas consist of two soft prongs that arise from oxygen supply tubing.(2) The prongs are inserted into the patient's anterior nares, and the tubing is secured to the patient's face. Oxygen flows from the cannula into the patient's nasopharynx, which acts as an anatomic reservoir.(3) The fractional concentration of inspired oxygen (FIO2) varies with the patient's inspiratory flow.(4)
2.1.2 Nasopharyngeal catheters are soft tubes with several distal holes. The catheter should be inserted into the patient's nose to a depth equal to the distance from the ala nasi to the tragus(5) or be gently advanced and then withdrawn until it rests slightly behind the uvula.(1) The tube, secured to the patient's face, is connected to oxygen supply tubing. Oxygen flows from the catheter into the patient's oropharynx, which acts as an anatomic reservoir.(6) The FIO2 varies with the patient's inspiratory flow.(1)
2.1.3 Tracheostomy oxygen adapters are devices that attach either directly to a tracheostomy tube or to a heat-moisture exchanger (HME), which is then attached to the tube. (HMEs or artificial noses collects a patient's expired heat and moisture and returns it during the following inspiration.(7)) The oxygen supply tube connected to the adapter provides a blow-by source of oxygen that results in a variable FIO2. These devices are intended for short periods such as brief transports or to increase patient mobility.(8)
2.1.4 Transtracheal catheters are devices that delivery gas directly into the trachea via a small percutaneous catheter held in place with a bead chain necklace.(9)
2.2 Reservoir systems:
2.2.1 Simple oxygen masks are plastic reservoirs designed to fit over the patient's nose and mouth and be secured around the patient's head by an elastic strap.(10) An increased reservoir effect is produced by adding the volume of the mask.(1) Oxygen is delivered through a small-bore tube connected to the base of the mask. Holes on each side of the mask provide an egress for exhaled gases and serve as room-air entrainment ports.(10) The FIO2 varies with the patient's inspiratory flow, mask fit and patient respiratory pattern.(1,11)
2.2.2 Partial-rebreathing masks are similar to simple oxygen masks but contain a reservoir at the base of the mask.(10) The reservoir receives fresh gas plus exhaled gas approximately equal to the volume of the patient's anatomic dead space.(10) The oxygen concentration of the exhaled gases combined with the supply of fresh oxygen, permits the use of flows lower than those necessary for other devices (eg, non-rebreathing masks), and potentially conserves oxygen use.
2.2.3 Non-rebreathing masks are similar to partial-rebreathing masks but do not permit the mixing of exhaled gases with the fresh gas supply.(10) A series of one-way valves ensures a fresh oxygen supply with minimal dilution from the entrainment of room air.(1) The one-way valve over the reservoir bag prevents entry of expired gas, and the one-way valve over one of the side ports limits entrainment of room air.(1) This design provides a higher FIO2 than the simple and partial-rebreathing masks and the nasal devices providing the mask fits correctly.(1)
2.3 High-flow systems:
2.3.1 An air-entrainment mask contains a jet orifice and air entrainment ports and is designed to fit over the patient's nose and mouth and is connected to oxygen supply tubing.(1) Oxygen under pressure is forced through a small jet orifice entering the mask. The velocity increases causing a shearing effect distal to the jet orifice, which causes room air to be entrained into the mask.(12) The total flow provided by the mask is determined by the cross-sectional area of the entrainment ports, the diameter of the jet orifice, and the oxygen flow to the jet. The FDO2 is determined by the dimensions of the jet and the entrainment ports. The entrainment mechanism is based on the principles described by Bernoulli.(12) A collar can be attached to the base of the corrugated hose for supplemental humidification,(13) and the device can be adapted to a tracheostomy collar.
2.3.2 Air-entrainment nebulizers are gas-powered, large-volume nebulizers that contain an adjustable air-entrainment port, which determines specific oxygen concentrations.(10,14) In addition to providing particulate water with or without added medication, heated nebulizers can deliver gas saturated with water vapor at body temperature.(15) A corrugated hose serves as a conduit from the nebulizer to an aerosol mask, face tent, tracheostomy collar, or T-piece.(13)
2.4 Enclosure Systems:
2.4.1 Oxygen hoods are transparent enclosures designed to surround the head of the neonate or small infant.(10,16) A continuous flow of humidified oxygen is supplied to the hood.(10,16) Transparent enclosures in larger sizes (so-called tent houses or huts) are available for patients who are too big for neonatal-size hoods.(13)
2.4.2 Closed incubators are transparent enclosures that provide a warm environment for small infants with temperature instability.(10) Supplemental oxygen can be added to incubators but may result in an increased oxygen concentration.(10) The primary purpose of an incubator is to provide a temperature-controlled environment. Humidification is available through a baffled blow-over water reservoir; however, due to the high risk of infection associated with this humidification system, alternative sources are used.(10) Therefore, the incubator is not further discussed as an oxygen delivery device.(13)

NPODD 3.0 SETTING:
Oxygen delivery devices are used in a number of settings including hospitals, clinics, extended care facilities, the home, and patient transport vehicles.

NPODD 4.0 INDICATIONS:
The selection of an oxygen delivery device is indicated with:

4.1 documented hypoxemia(17,18)
4.2 an acute situation in which hypoxemia is suspected or in which suspected regional hypoxia may respond to an increase in PaO2. Substantiation of PaO2 is required within an appropriate period of time following initiation of therapy.(17,18)

NPODD 5.0 CONTRAINDICATIONS:

5.1 No specific contraindications to delivering oxygen exist when indications are judged to be present.(18)
5.2 Nasal cannulas and nasopharyngeal catheters are contraindicated in patients with nasal obstruction (eg, nasal polyps, choanal atresia, etc).(10)
5.3 Nasopharyngeal catheters are contraindicated in the presence of maxillofacial trauma,(19) in patients in whom a basal skull fracture is present or suspected,(18) or coagulation problems exist.(1)
5.3.1 It is the expert opinion of the Clinical Practice Guideline Steering Committee (2002) that nasopharyngeal catheters are not appropriate for oxygen administration in the neonatal population.
5.4 Although opinions vary,(21-24) infants intubated for airway protection should probably be placed on CPAP (ie, physiologic CPAP) for supplemental oxygen rather than on a T-piece because of the loss of physiologic end-expiratory pressure created by an open glottis.

NPODD 6.0 HAZARDS/PRECAUTIONS/POSSIBLE COMPLICATIONS:

6.1 Physiologic:
6.1.1 The etiology of retinopathy of prematurity, especially the role of oxygen, is controversial. Care should be taken when supplemental oxygen is provided to preterm infants (< 37 weeks gestation). It is suggested that oxygen supplementation should not result in a PaO2 > 80 torr.(25)
6.1.2 The administration of supplemental oxygen to patients with certain congenital heart lesions (eg, hypoplastic left-heart, single ventricle) may cause an increase in alveolar oxygen tension and compromise the balance between pulmonary and systemic blood flow.(26-28)
6.1.3 The administration of supplemental oxygen to patients suffering from paraquat poisoning or to patients receiving certain chemotherapeutic agents (eg, bleomycin) may result in pulmonary complications (eg, oxygen toxicity and pulmonary fibrosis).(29,30)
6.1.4 Stimulation of the superior laryngeal nerves may cause alterations in respiratory pattern if the gas flow from the oxygen source is cool and is directed at the face of the infant.(31)
6.1.5 Inappropriate selection of FDO2 or oxygen flow may result in hypoxemia or hyperoxemia.
6.2 Equipment-related
6.2.1 Nasal cannulas:
6.2.1.1 Skin irritation can result from material used to secure the cannula(3,32) or from local allergic reaction to polyvinyl chloride.(33)
6.2.1.2 Improper sizing can lead to nasal obstruction or irritation.(3,34)
6.2.1.3 Displacement can lead to loss of oxygen delivery.(3)
6.2.1.4 Inadvertent CPAP may be administered depending upon the size of the nasal cannula, the gas flow, and the infant's anatomy.(35-37)
6.2.1.5 Irritation can result if flows are excessive.
6.2.2 Nasopharyngeal catheters:
6.2.2.1 Improper insertion can cause gagging6 and nasal or pharyngeal trauma.(6)
6.2.2.2 Improper sizing can lead to nasal obstruction or irritation.(3,34)
6.2.2.3 Excessive flow can produce pain in the frontal sinuses.(10)
6.2.2.4 Pneumocephalus is a rare but possible complication.(38)
6.2.2.4 Excessive secretions and/or mucosal inflammation can result.(5,39)
6.2.2.5 Skin irritation may result from material used to secure the cannula(3,32) and/or from local allergic reaction to polyvinyl chloride.(33)
6.2.2.6 Occlusion of distal openings may occur.(1)
6.2.2.7 Excessive flow may cause gastric distention.(1)
6.2.3 Transtracheal catheters:
6.2.3.1 Increase risk of infection compared to nasal cannulas and catheters(40,41)
6.2.3.2 Increased risk of complications(42-44)
6.2.4 Masks:
6.2.4.1 Aspiration of vomitus may be more likely when a mask is in place.
6.2.4.2 Irritation may result from tight application.(10,45)
6.2.4.3 Rebreathing of CO2 may occur if total O2 flow is inadequate.(14,46)
6.2.4.4 It is the expert opinion of the Clinical Practice Guideline Steering Committee (2002) that partial rebreathers or non-rebreathers are not appropriate for the neonatal population.
6.2.5 Air-entrainment nebulizers:
6.2.5.1 produce high noise levels in enclosed environments (eg, hoods, incubators) and may induce hearing impairment;(47) when an air-entrainment nebulizer is used in an enclosed environment, the entrainment port should be set on 100% (ie, closed) and the nebulizer powered either by a blender or by compressed air with titration of oxygen to the desired concentration.(13)
6.2.5.2 are susceptible to contamination;(48-50)
6.2.5.3 may cause bronchoreactivity in patients with reactive airways when used with nonisotonic solutions;(51)
6.2.5.4 may create unwanted torque and increase the likelihood of inadvertent extubation or decannulation of the patient when used with a T-piece and applied directly to an endotracheal or tracheostomy tube;(13)
6.2.5.5 may not provide particles of desired size range and in a predictable dose;(52)
6.2.5.6 if unheated, may induce cold stress in neonates;(31,53)
6.2.5.7 Condensate in tubing may result in advertent lavage when attached to the endotracheal tube.
6.2.6 Hoods and transparent enclosures:
6.2.6.1 Prolonged exposure to humidified oxygen may increase risk for cutaneous fungal infection.(54)
6.2.6.2 Inadequate or loss of gas flow may result in hypoxia or hypercapnia.
6.2.6.3 Temperature within enclosures should be closely monitored to reduce the potential for cold stress or apnea from overheating in neonates.(31,53)
6.2.6.4 Use of an improperly sized hood can result in irritation of the infant's skin.(13)
6.2.7 Tracheostomy oxygen adapters: Adapters may create unwanted torque and increase the likelihood of inadvertent decannulation of the patient, and HMEs may increase work of breathing to an unacceptable level in patients < 8 kg if dead space and resistance are high.(55)
6.3 During laser bronchoscopy, minimal levels of supplemental oxygen should be used to decrease the risk of intratracheal ignition.(18,56)
6.4 Fire hazard is increased in the presence of increased oxygen concentrations.(18)
6.5 Bacterial contamination has been associated with certain nebulization and humidification systems.(48-50)

NPODD 7.0 LIMITATIONS:

7.1 Nasal cannulas:
7.1.1 Changes in minute ventilation and inspiratory flow affect air entrainment and result in fluctuations in FIO2.(57-59)
7.1.2 Prongs are difficult to keep in position, particularly with small infants.(3,32,60)
7.1.3 The effect of mouth versus nose breathing on FIO2 remains controversial.(61-64)
7.1.4 Use may be limited by the presence of excessive mucus drainage, mucosal edema, or a deviated septum.(10)
7.1.5 Maximum flow should be limited to 2 L/min in infants and newborns.(35,57,58)
7.1.6 Care should be taken to keep the cannula tubing and straps away from the neck to prevent airway obstruction in infants.
7.1.7 Discrepancies between set and delivered flow can occur in the same flowmeter at different settings and among different flowmeters.
7.1.8 Discrepancies in flow and oxygen concentration between set and delivered values can occur in low-flow blenders at flows below the recommended range of the blender.
7.2 Nasopharyngeal catheters:
7.2.1 Method is in less common use because of the complexity of care.(34)
7.2.2 FIO2 is difficult to control and measure.(57,58)
7.2.3 Effect of mouth versus nose breathing on FIO2 remains controversial.(61-64)
7.2.4 Use may be limited by excessive mucus drainage, mucosal edema, or the presence of a deviated septum.(6)
7.2.5 Catheter should be cleared frequently to prevent occlusion of the distal holes.(5,6) The patient should be observed for evidence of catheter occlusion, and the catheter should be alternated between nares every 8-12 hours and changed daily.(65)
7.2.6 Catheter sizes less than 8 Fr are less effective in oxygen delivery.(5)
7.2.7 Lower oxygen concentrations are delivered if the catheter is placed in the nose rather than in the pharynx.(5)
7.2.8 Low-flow flowmeters (< 3 L/min) should be used.(5)
7.2.9 Discrepancies between set and delivered flow can occur in the same flowmeter at different settings and among different flowmeters.
7.2.10 Discrepancies in flow and oxygen concentration between set and delivered values can occur in low-flow blenders at flows below those recommended by the manufacturer.
7.3 Transtracheal catheters:
7.3.1 Method is in less common use because of the complexity of care.(1)
7.3.2 Requires frequent medical monitoring(1)
7.3.3 Replacement catheters are costly.(1)
7.3.4 Increased time needed for candidate evaluation and teaching(1)
7.4 Masks:
7.4.1 provide variable FIO2 depending on inspiratory flow and construction of the mask's reservoir(13) and are not recommended when precise concentrations are required;(66,67)
7.4.2 are confining and may not be well tolerated;(68)
7.4.3 interfere with feeding;(6)
7.4.4 may not be available in sizes appropriate for all patients;
7.4.5 require a minimum flow per manufacturer's instructions to avoid possible rebreathing of CO2.(14,31,46)
7.4.6 The maximum FIO2 attainable with a simple, non-rebreathing or partial-rebreathing mask in neonates, infants, and children has not been well documented.(46)
7.4.7 The performance of air-entrainment masks may be altered by resistance to flow distal to the restricted orifice (resulting in higher FDO2 and lower total flow delivered). The total flow from air-entrainment masks at settings greater than 0.(40) may not equal or exceed the patient's inspiratory flow.(10,18)
7.4.8 Performance is altered if the entrainment ports are blocked.
7.5 Air-entrainment nebulizers:
7.5.1 are vulnerable to alterations described in Section 7.4.7;
7.5.2 should have temperature monitored if they are heated. (Cool mist is not recommended for newborns because of the potential for cold stress.(31,53)) In newborns, the temperature of the gas-aerosol mixture at the patient should be approximately equal to the desired environmental temperature.(53)
7.5.3 may have performance altered by resistance to flow distal to the restricted orifice (resulting in higher FDO2 and lower total flow delivered). The total flow from air-entrainment nebulizers at settings greater than 0.(40) may fail to equal or exceed the patient's inspiratory flow.(10,18) However, increasing the oxygen flow to the inlet of the nebulizer may produce a higher delivered total flow.
7.6 Hoods:
7.6.1 O2 concentrations may vary within the hood.(10,13,18) O2 concentrations should be measured as near the nose and mouth as possible.(11) Opening any enclosure decreases the O2 concentration. For infants and children confined to hoods, nasal O2 may need to be supplied during feeding and nursing care. Flows > 7 L/min are required to wash out CO2.(13,14,31)
7.6.2 Devices can be confining and isolating.(13)
7.6.3 Concentration in a hood can be varied from 0.21 to 1.0.
7.6.4 Temperature of the gases in the hood should be maintained to provide a neutral thermal environment.(10,18,53)
7.6.5 High gas flows may produce harmful noise levels.(47,69)
7.7 Tracheostomy oxygen adapters provide variable FIO2s. HMEs should have minimum dead-space volume especially when used with neonates.(55,70,71) Resistance within an HME can increase when water is absorbed by the hygroscopic inserts(72) or when secretions are coughed into the device.(73)

NPODD 8.0 ASSESSMENT OF NEED:
Need is determined by measurement of inadequate oxygen tensions and saturations by invasive or noninvasive methods(74,75) and/or the presence of clinical indicators as previously described.(18) Supplemental oxygen flow should be titrated to maintain adequate oxygen saturation as indicated by pulse oximetry SpO2 or appropriate arterial or venous blood gas values.(76)

8.1 Nasal cannulas, nasopharyngeal catheters, and transtracheal catheters are used when the need exists to:
8.1.1 provide low-level supplemental oxygen to the infant or child;(57)
8.1.2 feed the infant without interrupting oxygen delivery;(6,77,78)
8.1.3 increase mobility.(6,77,78)
8.2 Simple oxygen masks are used to provide supplemental O2 in the moderate range (0.35-0.50, depending on size and minute ventilation) for short periods of time (eg, during procedures, for transport, in emergency situations).(14,18,79)
8.3 Partial rebreathing masks are used to conserve the oxygen supply when higher concentrations (FIO2 > 0.4, < 0.6) are warranted (eg, during transport).(14,18,62,79)
8.4 Non-rebreathing masks are used to deliver concentrations > or = 0.60 or specific concentrations (as from a blender).(1,18,79)
8.5 Air-entrainment masks provide a flow of gas of predetermined precise oxygen concentration (24-40%)(12,57,66-68) that exceeds the patient's inspiratory flow. At the 50% setting, the total flow from the device may not meet the inspiratory flow.(18,79)
8.6 Air-entrainment nebulizers, although not recommended, can be used when high levels of humidity or aerosol are desired (as with a bypassed upper airway).(51,80) The patient application device can be a tracheostomy collar, face tent, aerosol mask, or blow-by arrangement.(13,18,68)
8.7 Hoods are used to provide
8.7.1 controlled FIO2 in infant and small children;(10)
8.7.2 controlled FIO2 and/or increased heated humidity to patients who cannot tolerate other devices;
8.7.3 controlled FIO2 when the chest, abdomen, and extremities must be accessible to caregivers;(10)
8.7.4 the oxygen concentrations necessary for oxygen challenge (hyperoxia) tests in the spontaneously breathing neonate.
8.8 Tracheostomy oxygen adapters, which may or may not be coupled with HMEs, are used to deliver oxygen to a tracheostomy.(55)

NPODD 9.0 ASSESSMENT OF OUTCOME:
Outcome is assessed by determining whether the device selected produces an appropriate increase in oxygen saturation, proves to be appropriate for the patient, allows adequate patient monitoring, and facilitates patient care.

NPODD 10.0 RESOURCES:

10.1 Equipment
10.1.1 Oxygen source:
10.1.1.1 Cylinder -- must meet Department of Transportation (DOT) standards, Compressed Gas Association (CGA) standards, and National Fire Protection Association (NFPA) recommendations, and appropriate regulator and wrenches must be supplied;
10.1.1.2 Concentrators (or enrichers).(81,82)
10.1.1.3 Bulk supplies should meet NFPA standards.
10.1.2 Delivery accessory equipment:
10.1.2.1 oxygen tubing;
10.1.2.2 corrugated aerosol tubing and water trap.
10.1.3 Humidifiers -- No subjective or objective evidence supports routine humidification of O2 at flows < or = 4 L/min.81 However, it is not known whether the use of a bubble humidifier with a nasal cannula in the neonate has benefit, and the use of a bubble humidifier can verify oxygen delivery at flows < 1 L/min. HMEs with low dead space are appropriate for short-term use in patients with artificial airways.
10.1.4 Blenders -- Although blenders have been used in weaning neonates with a nasal cannula from oxygen, it appears that using a very-low flowmeter (0-200 mL) may be more reliable.(59,83)
10.1.5 Compensated, low-range flowmeters84 adjustable in increments < 0.125 L/min.(5,58,85)
10.1.6 Oxygen analyzers -- There are four principal types of oxygen analyzers; polargraphic, galvanic cell, paramagnetic, and wheatstone bridge. The polargraphic and galvanic cell are the two most commonly used and operate on an electrochemical principle.(86)
10.1.7 Noninvasive oxygen monitors -- transcutaneous (TcO2) monitor(74,86) or pulse oximeter.(75,87)
10.1.8 Nebulizer solutions -- sterile water or sterile normal saline solution.
10.2 Personnel:
10.2.1 Health care providers responsible for delivery of oxygen should have demonstrated and documented knowledge and skills related to:
10.2.1.1 oxygen delivery systems and their limitations;
10.2.1.2 assembly, care, and use of oxygen delivery systems;
10.2.1.3 performance of the necessary subjective and objective assessments in order to determine effectiveness of oxygen therapy;
10.2.1.4 clinical assessment skills to recommend changes in oxygen therapy;
10.2.1.5 provision of comprehensive patient and lay caregiver instruction.
10.2.2 When supplemental oxygen is to be used out of the hospital setting, the patient and/or family member or lay caregiver should:
10.2.2.1 demonstrate proper use and understanding of oxygen delivery device;
10.2.2.2 demonstrate proper assembly, care, and cleaning of oxygen delivery device;
10.2.2.3 demonstrate an understanding of how, when, and what to report to a physician or surrogate.

NPODD 11.0 MONITORING:

11.1 Patient:
11.1.1 clinical assessment including but not limited to cardiac, pulmonary, and neurologic status and apparent work of breathing;
11.1.2 assessment of physiologic variables: noninvasive or invasive measurement of oxygen tensions or saturation in any patient treated with oxygen -- within 1 hour of initiation for the neonate.(18,25,88)
11.2 Equipment:
11.2.1 All oxygen delivery systems should be checked at least once each day.18 More frequent checks by calibrated analyzer are necessary in systems:
11.2.1.1 susceptible to variation in oxygen concentration;(18)
11.2.1.2 applied to patients with artificial airways;(18)
11.2.1.3 Continuous analysis is recommended in hoods.(89)
11.2.1.4 Oxygen should be analyzed as close as possible to the infant's face.
11.2.2 All heated delivery systems should be continuously monitored for temperature.

NPODD 12.0 FREQUENCY:

12.1 Selection of a device is made at the initiation of therapy, after careful assessment of need and patient characteristics.
12.2 The change from one type of device to another is based on a change in the patient's condition, patient preference, or ability to use a specific device. (Oxygen therapy should be administered continuously unless the need has been shown to be associated only with specific situations, eg, exercise, feeding, or other stress.)(90,91)

NPODD 13.0 INFECTION CONTROL:
13.1 Universal Precautions and measures to limit the transmission of tuberculosis must be adhered to at all times.(92,93)
13.2 Low-flow systems
13.2.1 Under normal circumstances, low-flow oxygen systems do not present clinically important risk of infection and do not require routine replacement on the same patient.(18,94-96)
13.2.2 Nasopharyngeal catheters should be changed every 24 hours.(6)
13.2.3 Transtracheal catheters should be changed every 3 months.(97)
13.3 Reservoir systems -- Under normal circumstances, reservoir systems as defined for this guideline do not present clinically important risk of infection and do not require routine replacement on the same patient.
13.4 High-flow systems
13.4.1 Large-volume nebulizers should be changed every 24 hours when applied to patients with an artificial airway.(96)
13.4.2 In the absence of definitive studies to support change-out intervals on nonintubated patients, results of institution-specific and patient-specific surveillance measures should dictate the frequency with which such equipment is replaced.
13.5 Enclosure systems -- There is no recommendation regarding the frequency of changing oxyhood and reservoirs while in use on the same patient.(96)
13.6 Other devices -- Between patients, subject equipment (eg, probes, oxygen sensors) to high level disinfection.(96)
13.7 Nebulizer solutions -- Use only sterile fluids and dispense them aseptically.(96)

Note: It is the expert opinion of the Clinical Practice Guideline Steering Committee (2002) that some devices that are applicable to the pediatric population are not appropriate for the neonatal population.

Revised by Timothy R Myers RRT, University Hospitals of Cleveland, Cleveland, OH, and approved by the 2002 CPG Steering Committee.

Original publication: Respir Care 1996;41(7):637-646.

References
  1. Branson RD. Gas delivery systems: regulators, flowmeters, and therapy devices. In: Branson RD, Hess DR, Chatburn RL, editors. Respiratory care equipment, 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 1999:55-85.
  2. Kumar H, Antony TJ, Sharma D. Oxygen therapy in pediatric practice. Indian Pediatr 1993;30(1):117-121.
  3. Monin P, Vert P. The management of bronchopulmonary dysplasia. Clin Perinatol 1987;14(3):531-549.
  4. Ooi R, Joshi P, Soni N. An evaluation of oxygen delivery using nasal prongs. Anesthesia 1992;47(7):591-593.
  5. Shann F, Gatchalian S, Hutchinson R. Nasopharyngeal oxygen in children. Lancet 1988;2(8622):1238-1240.
  6. Guilfoile T, Dabe K. Nasal catheter oxygen therapy for infants. Respir Care 1981;26(1):35-40.
  7. Hess DR, Branson RD. Gas delivery systems: humidification. In: Branson RD, Hess DR, Chatburn RL, editors. Respiratory care equipment, 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 1999:101-132.
  8. Crimlisk JT, Murray SV. Home oxygen-humidity systems for an oxygen-dependent infant with tracheostomy: a case report. Respir Care 1988;33(12):1117-1124.
  9. Hoffman LA. Novel strategies for delivering oxygen: reservoir cannula, demand flow, and transtracheal oxygen administration. Respir Care 1994;39(4):363-377.
  10. Thalken FR. Medical gas therapy. In: Scanlan CL, Spearman CB, Sheldon RL, editors. Egan's fundamentals of respiratory care. St Louis: Mosby; 1990:606-632.
  11. Milross J, Young IH, Donnelly P. The oxygen delivery characteristics of the Hudson Oxy-one face mask. Anaesth Intensive Care 1989;17(2):180-184.
  12. Scacci R. Air entrainment masks: jet mixing is how they work; the Bernoulli and Venturi principles are how they don't. Respir Care 1979;24(10):928-931.
  13. Gramlich T. Oxygen therapy. In: Perinatal and pediatric respiratory care. Barnhart SL, Czervinske MP editors. Philadelphia: WB Saunders; 1995:156-179.
  14. McPherson SP. Gas regulation, administration, and controlling devices. In: McPherson SP, editor. Respiratory therapy equipment. St Louis: Mosby; 1990:50-78.
  15. Hill TV, Sorbello JG. Humidity outputs of large-reservoir nebulizers. Respir Care 1987;32(4):255-260.
  16. Thiebault DW, Gregory GA, editors. Neonatal pulmonary care, 2nd ed. Menlo Park CA: Addison-Wesley; 1986.
  17. Higgins TL, Yared J-P. Clinical effects of hypoxemia and tissue hypoxia. Respir Care 1993;38(6):603-615; discussion 615-617.
  18. American Association for Respiratory Care. AARC Clinical Practice Guideline: Oxygen therapy in the acute care facility -- 2002 revision and update. Respir Care 2002;47(6):xxx-xxx.
  19. Gregory JA, Turner PT, Reynolds AF. A complication of nasogastric intubation: intracranial penetration. J Trauma 1978;18(12):823-824.
  20. Fremstad JD, Martin SH. Lethal complication from insertion of nasogastric tube after severe basilar skull fracture. J Trauma 1978;18(12):820-822.
  21. Czervinske MP. Continuous positive airway pressure. In: Koff PB, Eitzman D, Neu J, editors. Neonatal and pediatric respiratory care, 2nd ed. St Louis: Mosby; 1993:265-284.
  22. Annest SJ, Gottlieb M, Paloski WH, Stratton H, Newell JC, Dutton R, Power SR Jr. Detrimental effects of removing end-expiratory pressure prior to endotracheal extubation. Ann Surg 1980;191(5):539-545.
  23. Berman LS, Fox WW, Raphaely RC, Downs JJ Jr. Optimal levels of CPAP for tracheal extubation of newborn infants. J Pediatr 1976;89(1):109-112.
  24. Smith RA. Physiologic PEEP. Respir Care 1988;33(7):620-629.
  25. Fetus and Newborn Committee of the AAP. Clinical considerations in the use of oxygen. In: Freeman RK, Poland RL, Hauth JC, Merenstein GB, editors. Guidelines for perinatal care. Elk Grove Village, IL: American Academy of Pediatrics and American College of Obstetricians and Gynecologists; 1992:197-203.
  26. El-Lessy HN. Pulmonary vascular control in hypoplastic left-heart syndrome: hypoxic- and hypercarbic-gas therapy. Respir Care 1995;40(7):737-742.
  27. Riordan CJ, Randsbeck F, Storey JH, Montgomery WD, Santamore WP, Austin EH 3rd. Effects of oxygen, positive end-expiratory pressure, and carbon dioxide on oxygen delivery in an animal model of the univentricular heart. J Thorac Cardiovasc Surg 1996;112(3):644-654.
  28. Day RW, Barton AJ, Pysher TJ, Shaddy RE. Pulmonary vascular resistance of children treated with nitrogen during early infancy. Ann Thorac Surg 1998;65(5):1400-1404.
  29. Fairshter RD, Rosen SM, Smith WR, Glauser FL, McRae DM, Wilson AF. Paraquat poisoning: new aspects of therapy. Q J Med 1976;45(180):551-565.
  30. Ingrassia TS 3rd, Ryu JH, Trastek VF, Rosenow EC 3rd. Oxygen-exacerbated bleomycin pulmonary toxicity. Mayo Clin Proc 1991;66(2):173-178.
  31. Bongianni F, Corda M, Fontana G, Pantaleo T. Influences of superior laryngeal afferent stimulation on expiratory activity in cats. J Appl Physiol 1988;65(1):385-392.
  32. Rotschild A, Schapira D, Kuyek N, Solimano A. Evaluation of nasal prongs of new design for low-flow oxygen delivery to infants. Respir Care 1989;34(9):801-804.
  33. McLaughlin AJ Jr. Allergic contact dermatitis from oxygen cannulas. Respir Care 1980;25(10):1024-1026.
  34. Weber MW, Palmer A, Oparaugo A, Mulholland EK. Comparison of nasal prongs and nasopharyngeal catheter for the delivery of oxygen in children with hypoxemia because of a lower respiratory tract infection. J Pediatr 1995;127(3):378-383.
  35. Locke RG, Wolfson MR, Shaffer TH, Rubenstein SD, Greenspan JS. Inadvertent administration of positive end-distending pressure during nasal cannula flow. Pediatrics 1993;91(1):135-138.
  36. Sreenan C, Lemke RP, Hudson-Mason A, Osiovich H. High-flow nasal cannulae in the management of apnea of prematurity: a comparison with conventional nasal continuous positive airway pressure. Pediatrics 2001;107(5):1081-1083.
  37. Courtney SE, Pyo, KH, Saslow JG, Arnold GK, Pandit PB, Habib RH. Lung recruitment and breathing pattern during variable versus continuous flow nasal continuous positive airway pressure in premature infants: an evaluation of three devices. Pediatrics 2001;107(2):304-308.
  38. Frenckner B, Ehrén H, Palmér K, Norén G. Pneumocephalus caused by a nasopharyngeal oxygen catheter. Crit Care Med 1990;18(11):1287-1288.
  39. Muhe L, Degefu H, Worku B, Oljira B, Mulholland EK. Comparison of nasal prongs with nasal catheters in the delivery of oxygen to children with hypoxia. J Trop Pediatr 1998;44(6):365-368.
  40. Adamo JP, Mehta AC, Stelmach K, Meeker D, Rice T, Stoller JK. The Cleveland Clinic's initial experience with transtracheal oxygen therapy. Respir Care 1990;35(2):153-160.
  41. Crouser JI Jr, Make BJ. Respiratory tract infection complicating transtracheal oxygen therapy. Chest 1992;101(1):273-275.
  42. Burton GG, Wagshul FA, Henderson D, Kime SW. Fatal obstruction caused by a mucous ball from transtracheal oxygen catheter. Chest 1991;99(6):1520-1523.
  43. Punzal PA, Myers R, Ries AL, Harrell JH 2nd. Laser resection of granulation tissue secondary to transtracheal oxygen catheter. Chest 1992;101(1):269-271.
  44. Roth BJ, Irvine TW, Liening DA, Duncan NO, Cragun WHC. Acute respiratory compromise resulting from tracheal mucous impaction secondary to a transtracheal oxygen catheter. Chest 1992;101(5):1465-1466.
  45. Kacmarek RM. Methods of oxygen delivery in the hospital. Probl Respir Care 1990;3:563-574.
  46. Jensen AG, Johnson A, Sandstedt S. Rebreathing during oxygen treatment with face mask: the effect of oxygen flow rates on ventilation. Acta Anaesthesiol Scand 1991;35(4):289-292.
  47. Beckham RW, Mishoe SC. Sound levels inside incubators and oxygen hoods used with nebulizers and humidifiers. Respir Care 1982;27(1):33-40.
  48. Reinarz JA, Pierce AK, Mays BB, Sanford JP. The potential role of inhalation therapy equipment in nosocomial pulmonary infections J Clin Invest 1965;44:831-839.
  49. Pierce AK, Sanford JP, Thomas GD, Leonard JS. Long-term evaluation of decontamination of inhalation-therapy equipment and the occurrence of necrotizing pneumonia. N Engl J Med 1970;282(10):528-531.
  50. U.S. Department of Health and Human Services, Public Health Services, Centers for Disease Control. Guideline for prevention of nosocomial pneumonia and guideline ranking scheme. Atlanta: CDC, 1982.
  51. American Association for Respiratory Care. AARC Clinical practice guideline: Bland aerosol therapy. Respir Care 1993;38(11):1196-1199.
  52. Brain J. Aerosol and humidity therapy. Am Rev Respir Dis 1980;122(5 Pt 2):17-21.
  53. Scopes JW, Ahmed I. Ranges of critical temperatures in sick and premature newborn babies. Arch Dis Child 1966;41:417-419.
  54. Lanska MJ, Silverman R, Lanska DJ. Cutaneous fungal infections associated with prolonged treatment in humidified oxygen hoods (letter). Pediatr Dermatol 1987;4(4):346.
  55. Duncan A. Use of disposable condenser humidifiers in children (letter). Anaesth Intensive Care 1985;13(3):330.
  56. Schramm VL Jr, Mattox DE, Stool SE. Acute management of laser-ignited intratracheal explosion. Laryngoscope 1981;91(9 Pt 1):1417-1426.
  57. Fan LL, Voyles JB. Determination of inspired oxygen delivered by nasal cannula in infants with chronic lung disease. J Pediatr 1983;103(6):923-925.
  58. Vain NE, Prudent LM, Stevens DP, Weeter MM, Maisels MB. Regulation of oxygen concentration delivered to infants via nasal cannulas. Am J Dis Child 1989;143(12):1458-1460.
  59. Finer NN, Bates R, Tomat P. Low flow oxygen delivery via nasal cannula to neonates. Pediatr Pulmonol 1996;21(1):48-51.
  60. Thilo EH, Comito J, McCulliss D. Home oxygen therapy in the newborn: costs and parental acceptance. Am J Dis Child 1987;141(7):766-768.
  61. Poulton TJ, Comer PB, Gibson RL. Tracheal oxygen concentrations with a nasal cannula during oral and nasal breathing. Respir Care 1980;25(7):739-741.
  62. Kory RC, Bergmann JC, Sweet RD, Smith JR: Comparative evaluation of oxygen therapy techniques. JAMA 1962;179(10):767-772.
  63. Gibson RL, Comer PB, Beckham RW, McGraw CP. Actual tracheal oxygen concentrations with commonly used oxygen equipment. Anesthesiology 1976;44(1):71-73.
  64. Dunlevy CL, Tyl SE. The effect of oral versus nasal breathing on oxygen concentrations received from nasal cannulas. Respir Care 1992;37(4):357-360.
  65. Givan DC, Wylie P. Home oxygen therapy for infants and children. Indiana Med 1986;79(10): 849-853.
  66. Cox D, Gillbe C. Fixed performance oxygen masks: hypoxic hazard of low-capacity drugs. Anaesthesia 1981;36(10):958-964.
  67. Woolner DF, Larkin J. An analysis of the performance of a variable venturi-type oxygen mask. Anaesth Intensive Care 1980;8(1):44-51.
  68. Amar D, Brodman LE, Winikoff SA, Hollinger I. An alternative oxygen delivery system for infants and children in the post-anaesthesia care unit. Can J Anaesth 1991;38(1):49-53.
  69. Mishoe SC, Brooks CW Jr, Dennison FH, Hill KV, Frye T. Octave waveband analysis to determine sound frequencies and intensities produced by nebulizers and humidifiers used with hoods. Respir Care 1995; 40(11):1120-1124.
  70. Branson RD, Hurst JM. Laboratory evaluation of moisture output of seven airway heat and moisture exchangers. Respir Care 1987;32(9):741-747.
  71. Gedeon A, Mebius C, Palmer K. Neonatal hygroscopic condenser humidifier. Crit Care Med 1987;15(1):51-54.
  72. Mapleson WW, Morgan JG, Hillard EK. Assessment of condenser-humidifiers with special reference to a multiple-gauze model. Br Med J 1963;1:300-305.
  73. Shelly M, Bethune DW, Latimer RD. A comparison of five heat and moisture exchangers. Anaesthesia 1986;41(5):527-532.
  74. American Association for Respiratory Care.AARC Clinical practice guideline: transcutaneous blood gas monitoring for neonatal and pediatric patients. Respir Care 1994;39(12):1176-1179.
  75. American Association for Respiratory Care. AARC Clinical practice guideline: pulse oximetry. Respir Care 1991;36(12):1406-1409.
  76. Nelson LD. Assessment of oxygenation: oxygenation indices. Respir Care 1993;38(6):631-640; discussion 641-645.
  77. Pinney MA, Cotton EK. Home management of bronchopulmonary dysplasia. Pediatrics 1976;58(6):856-859.
  78. Voyles JB. Bronchopulmonary dysplasia. Am J Nurs 1981;81(3):510-514.
  79. Redding JS, McAfee DD, Gross CW. Oxygen concentrations received from commonly used delivery systems. South Med J 1978;71(2):169-172.
  80. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, November 1986. Am Rev Respir Dis 1987;136(1):225-244.
  81. Campbell EJ, Baker MD, Crites-Silver P. Subjective effects of humidification of oxygen for delivery by nasal cannula: a prospective study. Chest 1988;93(2):289-293.
  82. Lucas J, Golish J, Sheeper G, O'Rayne J. Home respiratory care. East Norwalk CT: Appleton & Lange; 1987.
  83. Benaron DA, Benitz WE. Maximizing the stability of oxygen delivered via nasal cannula. Arch Pediatr Adolesc Med 1994;148(3):294-300.
  84. O'Donohue WJ Jr, Baker JP. Controlled low-flow oxygen in the management of acute respiratory failure. Chest 1973;63(5):818-821.
  85. Zinman R, Franco I, Pizzuti-Daechsel R. Home oxygen delivery system for infants. Pediatr Pulmonol 1985:1(6):325-327.
  86. Hess DR, Branson RD. Noninvasive respiratory monitoring equipment. In: Branson RD, Hess DR, Chatburn RL, editors. Respiratory care equipment, 2nd ed. Philadelphia: Lippincott Williams & Wilkins 1999:247-282.
  87. Jennis MS, Peabody JL. Pulse oximetry: an alternative method for assessment of oxygenation in newborn infants. Pediatrics 1987;79(4):524-528.
  88. American Academy of Pediatrics, American College of Obstetricians and Gynecologists. Guidelines for perinatal care, 2nd ed. 1988:246-247.
  89. Salyer JW, Chatburn RL. Patterns of practice in neonatal and pediatric respiratory care. Respir Care 1990;35(9):879-888.
  90. Speidel BD. Adverse effects of routine procedures on preterm infants. Lancet 1978;1(8069):864-866.
  91. Long JG, Philip AGS, Lucey JF. Excessive handling as a cause of hypoxemia. Pediatrics 1980;65(2):203-207.
  92. Update: universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus, and other bloodborne pathogens in health-care settings. MMWR Morb Mortal Wkly Rep 1988;37(24):377-382, 387-388.
  93. Dooley SW Jr, Castro KG, Hutton MD, Mullan RJ, Polder JA, Snider DE Jr. Guidelines for preventing the transmission of tuberculosis in health-care settings, with special focus on HIV-related issues. MMWR Recomm Rep 1990;39(RR-17):1-29.
  94. Seigel D, Romo B. Extended use of prefilled humidifier reservoirs and the likelihood of contamination. Respir Care 1990;35(8);806-810.
  95. Golar SD, Sutherland LLA, Ford GT. Multipatient use of prefilled disposable oxygen humidifiers for up to 30 days: patient safety and cost analysis. Respir Care 1993;38(4):343-347.
  96. Tablan OC, Anderson LJ, Arden NH, Breiman RF, Butler JC, McNeil MM, and the Hospital Infection Control Practices Advisory Committee. Centers for Disease Control. Guideline for the prevention of nosocomial pneumonia. Respir Care 1994;39(12):1191-1236.
  97. SCOOP transtracheal oxygen therapy clinician guide. Englewood CO; Transtracheal Systems, 1990.

Interested persons may copy these Guidelines for noncommercial purposes of scientific or educational advancement. Please credit AARC and Respiratory Care Journal.

Reprinted from the June 2002 issue of RESPIRATORY CARE [Respir Care 2002;47(6):707–716]

You are here: RCJournal.com » Clinical Practice Guidelines